Figure 3.

Signaling pathways involved in IL-22-mediated intestinal LS174T cell proliferation. Cells were pre-treated with inhibitors against (A) STAT1 (50 μM), (B) STAT3 (50 μM), (C) STAT5 (50 μM), (D) Akt (10 μM), (E) p38 (10 μM), or (F) ERK (10 μM) alone for 1 h and then observed in the absence or presence of IL-22 (50 ng/mL) for 36 h. Data are presented as mean ± SEM of percentage of increased confluency at each time point of the cell proliferation assay (n = 6, two independent experiments). **** p < 0.0001 compared with control or IL-22 as indicated (two-way ANOVA followed by Bonferroni’s post-hoc test).